One-Year Outcomes in the Propensity-Matched Sample, by Anticoagulant Class at Outcome (N = 1,866; 1,618 Person-Years)
| Outcome | VKA, No. (%) | DOAC, No. (%) | Total, No. (%) | HR (95% CI) |
|---|---|---|---|---|
| ≥1 arterial or venous event | 15 (1.9) | 14 (1.9) | 29 (1.9) | 1.00 (0.48-2.07) |
| Any bleeding | 38 (4.9) | 55 (7.4) | 93 (6.1) | 0.65 (0.43-0.98) |
| Major bleeding | 8 (1.0) | 17 (2.3) | 25 (1.6) | 0.45 (0.19-1.03) |
| Nonmajor but clinically relevant bleeding | 21 (2.7) | 22 (2.9) | 43 (2.8) | 0.90 (0.50-1.64) |
| Minor bleeding | 9 (1.1) | 16 (2.1) | 25 (1.6) | 0.52 (0.23-1.18) |
| All-cause death | 40 (5.0) | 19 (2.5) | 59 (3.8) | 1.98 (1.15-3.42) |
| Sudden death/dysrhythmia | 10 (1.3) | 1 (0.1) | ... | ... |
| Heart failure | 4 (0.5) | 3 (0.4) | ... | ... |
| Myocardial infarction | 1 (0.1) | 0 (0) | ... | ... |
| Ischemic stroke/systemic embolism (other than embolic stroke) | 0 (0) | 2 (0.3) | ... | ... |
| Hemorrhagic stroke | 1 (0.1) | 1 (0.1) | ... | ... |
| Extracranial hemorrhage | 1 (0.1) | 5 (0.7) | ... | ... |
| Other vascular death | 1 (0.1) | 1 (0.1) | ... | ... |
| Malignancy | 7 (0.9) | 1 (0.1) | ... | ... |
| Infection | 8 (1.0) | 0 (0) | ... | ... |
| Respiratory | 0 (0) | 2 (0.3) | ... | ... |
| Trauma/accidental | 0 (0) | 1 (0.1) | ... | ... |
| Hepatobiliary/liver failure | 0 (0) | 1 (0.1) | ... | ... |
| All other nonvascular death | 0 (0) | 0 (0) | ... | ... |
| Undetermined death | 7 (0.9) | 1 (0.1) | ... | ... |
DOAC = direct oral anticoagulant; HR = hazard ratio; VKA = vitamin K antagonist.